Item 3. Source and Amount of Funds or Other Consideration
Item 3 of the Original Schedule 13D is hereby amended and supplemented by adding the information set forth in Item 4 of this Amendment No. 28, which is incorporated herein by reference, and by adding the following information:
As of the date of this Amendment No. 28, the aggregate outstanding principal amount under the Facilities Agreement related to the Offeror’s mandatory public takeover bid to purchase all outstanding Ordinary Shares of the Issuer that the Offeror and its affiliates did not already own which expired on March 15, 2024, and was consummated on April 3, 2024 (the “Completed Mandatory Bid”), is approximately $500 million.
Item 4. Purpose of the Transaction
Item 4 of the Original Schedule 13D is hereby amended and supplemented by adding the following information:
FSMA Order
On September 8, 2024, the Issuer issued a press release announcing that the Market Court in Belgium (the “Market Court”) had issued its ruling on September 6, 2024 which largely rejected the claims brought by certain funds managed by FourWorld Capital Management, LLC (“FourWorld”) in connection with the Completed Mandatory Bid.
FourWorld’s application sought, among other things, to challenge the price paid in the Completed Mandatory Bid, alleging that it did not reflect certain purported special benefits that were allegedly granted to Frontline in connection with the sale of certain vessels by the Issuer to Frontline in addition to the price paid by the Offeror for the shares of the Issuer owned by Frontline. FourWorld also requested that the Market Court order the Offeror to adjust the bid price in the Completed Mandatory Bid to account for these alleged special benefits. In its ruling dated September 6, 2024, the Market Court dismissed the majority of FourWorld’s claims as inadmissible and/or unfounded. However, the Market Court found that the pricing of certain vessels sold by the Issuer to Frontline implied certain special benefits to Frontline. The Market Court calculated these benefits to be $0.52 per share. The Market Court did not order CMB or the Financial Services and Markets Authority of Belgium (the “FSMA”) to increase the bid price, but rather the judgment indicated that the FSMA retained discretionary authority to decide whether such a bid price increase is warranted.
On October 7, 2024, the FSMA ordered CMB to (i) pay $0.52 per share to all shareholders whose shares were validly tendered in the Offers that closed on March 15, 2024 and (ii) reopen the Belgian Offer at an adjusted offer price of $12.66 per share (the “Adjusted Offer Price”). The Adjusted Offer Price takes into account the initial reference price of the Offers of $18.43, increased by $0.52, in accordance with the order by the FSMA, and decreased by $6.29 (the aggregate amount of distributions made by the Issuer since the initial announcement of the Belgian Offer on October 9, 2023).
Additional Payment Relating to the Offers
As ordered by the FSMA in the FSMA Order, CMB will pay to all shareholders whose shares were validly tendered in the Offers that closed on March 15, 2024, an additional $0.52 per share (the “Subsequent Payment”). As CMB previously announced, 69,241,955 Ordinary Shares were validly tendered in the prior Offers. CMB expects to make the Subsequent Payment (totaling approximately $36.0 million) as ordered by the FSMA on October 31, 2024.
The Belgian Reopening and the New U.S. Tender Offer
The FSMA also ordered CMB to reopen its unconditional mandatory public takeover bid (the “Belgian Reopening”) for all Ordinary Shares of the Issuer that CMB and its affiliates do not already own in accordance with the provisions of the Act of 1 April 2007 on takeover bids (the “Takeover Act”) and Chapter III of the Royal Decree of 27 April 2007 on takeover bids (the “Takeover RD”) at the Adjusted Offer Price.
On October 9, 2024 CMB issued a press release announcing that it will commence the Belgian Reopening which will be conducted concurrently with a new tender offer open to shareholders of the Issuer that are resident in the United States (the “New U.S. Tender Offer”) at the Adjusted Offer Price. The Adjusted Offer Price may be reduced on a dollar-for-dollar basis by the gross amount per share of any future distributions by the Issuer to its shareholders with a payment date prior to the settlement date of the Belgian Reopening and the New U.S. Tender Offer.